Research report on “Adrenoleukodystrophy (ALD) Market” offers the breakdown of the business by market Size, growth rate, key companies, regions, product types and applications. The Adrenoleukodystrophy (ALD) Market size report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Adrenoleukodystrophy (ALD) market share, enterprise competition outline, benefits and drawbacks of the market, Adrenoleukodystrophy (ALD) industry development trends, regional industrial layout features and economics policies, industry news and strategies by regions has additionally been enclosed.
Get Sample Copy of Report @https://www.industryresearch.co/enquiry/request-sample/14792378
Adrenoleukodystrophy Pipeline Overview:
Adrenoleukodystrophy is a fatal progressive neurogenerative disorder affecting brain white matter. The common form of ALD is X-linked (X-ALD) and results from mutation of ABCD1 encoded very long chain fatty acid (VLCFA) transporter. It is clinically heterogeneous with the cerebral form being the most severe. X-linked Adrenoleukodystrophy (X-ALD) is a rare X-linked metabolic disorder caused by variants in the ABCD1 gene which causes a deficiency in adrenoleukodystrophy protein (ALDP) and subsequent accumulation of very long chain fatty acids (VLCFA).The symptoms of Adrenoleukodystrophy are highly variable. There are mainly three types which are present in approximately 90-95% of the affected people: a childhood cerebral form; an adrenomyeloneuropathy type; and an adrenal insufficiency only type.The diagnosis of ALD, therefore, can be made with the highly sensitive and specific plasma VLCFA assay. When an abnormal pattern is detected with an identifiable ABCD1 mutation in a presymptomatic patient (or in the setting of classic clinical disease in others), males are determined to have the biochemical defect of ALD. Disease may manifest at any age. Most ALD males will develop primary adrenal insufficiency (AI) in childhood or adolescence, and most surviving males will develop spinal cord disease (adrenomyeloneuropathy [AMN]) during adulthood.The therapeutic pipeline of Adrenoleukodystrophy consists of approximately 9+ products in different stages of development. Currently, 3+ drugs are in Phase III development and major drugs are in late stage.
For More Information or Query or Customization Before Buying, Visit at-https://www.industryresearch.co/enquiry/pre-order-enquiry/14792378
Top Company AnalysedSome of the key players include Applied Genetic Technologies Corporation; Bluebird bio; Magenta Therapeutics; MedDay Pharmaceuticals; Minoryx Therapeutics; NeuroVia; Orpheris; ReceptoPharm; SOM Biotech; and Viking Therapeutics.
Scope of the report:• Provides an overview of therapeutic pipeline activity for Adrenoleukodystrophy across the complete product development cycle including all clinical and non-clinical stages• The report comprises of detailed profiles of Adrenoleukodystrophy therapeutic products with key coverage of developmental activities including licensing and collaboration deals, patents issued, designations, technologies and chemical information• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration• Detailed profiles of the discontinued products have been included in the report
Key Deliverables of the report:
Purchase this Report (Price 1500 USD for a Single-User License)-https://www.industryresearch.co/purchase/14792378
Key TOC Points in the Adrenoleukodystrophy (ALD) Market Report:
1 Market Introduction
Market Definition
Objective of the Study
Limitation
Stakeholders
Currency used in the Report
2 Research Methodology or Assumption
Research Methodology for Adrenoleukodystrophy (ALD) Market Study
Main objective of the Adrenoleukodystrophy (ALD) Market Study
3 Industry Performance
4 Executive Summary
5 Market Overview
Market Dynamics
Market Drivers
Market Restraints
6 Market Insights by Component
7 Adrenoleukodystrophy (ALD) Market Insights by Technology
8 Adrenoleukodystrophy (ALD) Market Insights by Application
9 Adrenoleukodystrophy (ALD) Market Insights by End-User Industry
10 Adrenoleukodystrophy (ALD) Market Insights by Region
11 Competitive Scenario
Porter’s Five forces analysis
Adrenoleukodystrophy (ALD) Market Share Analysis
12 Company Profiles
Browse Complete TOC at:https://www.industryresearch.co/TOC/14792378#TOC
Contact Us:
Name: Ajay More
Phone: US +1424 253 0807/ UK +44 203 239 8187
Email ID: sales@industryresearch.co
Our Other Reports:
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit Adrenoleukodystrophy (ALD) Market 2020 Status, Growth Rate by Applications, and Future Forecast 2025